ストックスクリーナーアプリを入手
13.58
12.50%
-1.94
アフターアワーズ：
13.45
-0.13
-0.96%
Edgewise Therapeutics Inc (EWTX) 最新ニュース
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 7.3%Should You Sell? - MarketBeat
Edgewise Therapeutics Downgraded Following Safety Issues in Heart Drug Trial - Yahoo Finance
Edgewise Therapeutics Downgraded Following Safety Issues in Hear - GuruFocus
Edgewise Therapeutics Says Believes Atrial Fibrillation Not Driven by EDG-7500 in Phase 2 Trial, RBC Says - MarketScreener
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by American Century Companies Inc. - MarketBeat
Edgewise Therapeutics downgraded at Scotiabank on heart disease trial results - Seeking Alpha
Edgewise shares slide amid trial and stock news - The Pharma Letter
RBC Capital cuts Edgewise Therapeutics target to $52 By Investing.com - Investing.com UK
Edgewise’s HCM Candidate May Provide Advantages Over BMS’s Camzyos - insights.citeline.com
Edgewise Therapeutics selling $200M in stock to support drug commercialization - BizWest
Edgewise down on atrial fibrillation; cardiomyopathy data positive - BioWorld MedTech
Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On (EWTX) - Seeking Alpha
Why These Two Biotech Stocks Just Diverged - Investor's Business Daily
Edgewise Therapeutics sets $20.13 share price in $200 million stock offering By Investing.com - Investing.com South Africa
Edgewise reports promising HCM trial results for EDG-7500 By Investing.com - Investing.com South Africa
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - Investopedia
CYTK Gains as EWTX Data and Fundraising Impact Stock Movement - GuruFocus
Edgewise stock holds Buy rating, $50 target from Truist Securities By Investing.com - Investing.com UK
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study - Benzinga
Why Edgewise Therapeutics (EWTX) Stock Is Falling - Benzinga
Edgewise falls on safety, efficacy doubts for heart disease drug - TradingView
Cytokinetics stock rises on Edgewise data for lead drug (EWTX) - Seeking Alpha
Edgewise Therapeutics stock tumbles after trial results and stock offering By Investing.com - Investing.com Australia
Edgewise Therapeutics stock tumbles after trial results and stock offering - Investing.com India
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - BioSpace
Edgewise Therapeutics sets $20.13 share price in $200 million stock offering - Investing.com Australia
Edgewise Therapeutics Prices 9.9 Mln Offering At $20.13/shr; Stock Fell In Pre-market - Nasdaq
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 Cirrus-Hcm Four-Week Trial of Edg-7500 in Hypertrophic Cardiomyopathy - MarketScreener
Edgewise’s heart drug shows promise in Phase 2 trial - Endpoints News
Edgewise Therapeutics Reports New Results From Phase 2 Hypertrophic Cardiomyopathy Trial - MarketScreener
Edgewise reports promising HCM trial results for EDG-7500 - Investing.com India
Edgewise Therapeutics Prices $200 Million Offering - MarketScreener
Edgewise Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Edgewise Therapeutics announces top-line data of EDG-7500 from CIRRUS-HCM trial - TipRanks
Why Edgewise Therapeutics Is Rising In Pre-market? - Nasdaq
$200M Funding Positions Edgewise to Launch Breakthrough Muscular Dystrophy Treatment - Stock Titan
Edgewise Therapeutics Announces Positive Top-Line Results From Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy - MarketScreener
Teacher Retirement System of Texas Buys 1,772 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Artisan Partners Limited Partnership Increases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Hypertrophic Cardiomyopathy Market to Show Remarkable Growth - openPR.com
Quantbot Technologies LP Invests $103,000 in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 9.3%Still a Buy? - MarketBeat
EFG Asset Management North America Corp. Acquires New Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Brokerages Set Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Price Target at $45.38 - MarketBeat
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Benzinga
Intech Investment Management LLC Boosts Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Major Phase 2 Trial Results: Edgewise's New HCM Drug Could Transform Patient Care - Stock Titan
EDG-4131 active in model of Becker muscular dystrophy - BioWorld MedTech
Victory Capital Management Inc. Takes Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Charles Schwab Investment Management Inc. Has $14.35 Million Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 3.5%Should You Sell? - MarketBeat
1.23%
1.63%
大文字化:
|
ボリューム (24 時間):